Acosta Úrsula, Bebia Vicente, Torné Aureli, Carreras-Dieguez Nuria, Glickman Ariel, Pérez-Benavente Asunción, Díaz-Feijoo Berta, Gil-Moreno Antonio
Gynecologic Oncology Department, Vall Hebron University Hospital, Barcelona, Spain.
Gynecologic Oncology Department, Vall Hebron University Hospital, Barcelona, Spain.
Gynecol Oncol. 2025 Jul;198:49-54. doi: 10.1016/j.ygyno.2025.05.014. Epub 2025 May 24.
Lymph node (LN) metastasis is a key prognostic factor in locally advanced cervical cancer (LACC), especially at the aortic level. Prophylactic extended-field radiotherapy (EFRT) indications are being evaluated, as imaging (r) may miss low-volume aortic LN disease in patients with pelvic LN metastasis. Our aim was to describe the distribution of pelvic and aortic LN metastasis confirmed by histology in patients with FIGO stage IIIC1r LACC.
This multicenter retrospective study included women with FIGO stage IIIC1r LACC treated with chemoradiotherapy and pretherapeutic nodal surgical staging with laparoscopic extraperitoneal aortic lymphadenectomy to the left renal vein and debulking of pathological pelvic LN on imaging. Imaging for stage IIIC1r diagnosis included MRI and/or PET-scan. LN metastasis distribution was categorized by location: pelvic or aortic and supra- or inframesenteric.
We included 164 patients, 96.3 % evaluated with MRI and 35 % with PET-scan. The median number of excised LN was 12 aortic and 8.5 pelvic. Pelvic LN metastasis was confirmed in 73 patients (44.5 %), of whom 31 (42.5 %) had aortic LN metastasis: 24.7 % inframesenteric, 4.1 % supramesenteric, and 13.7 % both. Pelvic LN were negative in 96 patients (58.5 %), of whom 11 (11.5 %) had aortic LN metastasis: 7.3 % inframesenteric, 3.1 % supramesenteric, and 1 % both.
In stage IIIC1r LACC, pelvic LN metastasis are confirmed in less than 50 % of patients following surgical evaluation. The risk of aortic LN involvement is higher when there are metastases at the pelvic level but not exclusively. The rate of supramesenteric disease supports extending the EFRT to the left renal vein.
淋巴结(LN)转移是局部晚期宫颈癌(LACC)的关键预后因素,尤其是主动脉水平的转移。由于影像学检查(r)可能会遗漏盆腔LN转移患者的小体积主动脉LN疾病,预防性扩大野放疗(EFRT)的指征正在评估中。我们的目的是描述国际妇产科联盟(FIGO)IIIC1r期LACC患者经组织学证实的盆腔和主动脉LN转移分布情况。
这项多中心回顾性研究纳入了接受放化疗以及术前通过腹腔镜腹膜外主动脉淋巴结清扫至左肾静脉进行淋巴结手术分期并对影像学上的病理性盆腔LN进行减瘤治疗的FIGO IIIC1r期LACC女性患者。IIIC1r期诊断的影像学检查包括MRI和/或PET扫描。LN转移分布按位置分类:盆腔或主动脉以及肠系膜上或肠系膜下。
我们纳入了164例患者,96.3%接受了MRI评估,35%接受了PET扫描。切除的LN中位数为主动脉旁12个和盆腔8.5个。73例患者(44.5%)证实有盆腔LN转移,其中31例(42.5%)有主动脉LN转移:肠系膜下24.7%,肠系膜上4.1%,两者均有13.7%。96例患者(58.5%)盆腔LN为阴性,其中11例(11.5%)有主动脉LN转移:肠系膜下7.3%,肠系膜上3.1%,两者均有1%。
在IIIC1r期LACC中,手术评估后不到50%的患者证实有盆腔LN转移。当盆腔有转移时主动脉LN受累的风险更高,但并非唯一。肠系膜上疾病的发生率支持将EFRT扩展至左肾静脉。